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ABSTRACT
Objective: To report the clinical features, comorbidities, receptor subunit targets, and outcome in
patients with anti-GABAA receptor (GABAAR) encephalitis.
Methods: Clinical study of 26 patients, including 17 new (April 2013–January 2016) and 9
previously reported patients. Antibodies to a1, b3, and g2 subunits of the GABAAR were
determined using reported techniques.
Results: Patients’ median age was 40.5 years (interquartile range 48.5 [13.75–62.35] years; the
youngest 2.5 months old; 13 female). Symptoms included seizures (88%), alteration of cognition
(67%), behavior (46%), consciousness (42%), or abnormal movements (35%). Comorbidities
were identified in 11 (42%) patients, including 7 tumors (mostly thymomas), 2 herpesvirus
encephalitis (herpes simplex virus 1, human herpesvirus 6; coexisting with NMDAR antibodies),
and 2 myasthenia without thymoma. Brain MRI was abnormal in 23 (88%) patients, showing in
20 (77%) multifocal, asynchronous, cortical-subcortical T2/fluid-attenuated inversion recovery
abnormalities predominantly involving temporal (95%) and frontal (65%) lobes, but also basal
ganglia and other regions. Immunologic or tumor therapy resulted in substantial improvement in
18/21 (86%) assessable patients; the other 3 (14%) died (2 status epilepticus, 1 sepsis). Com-
pared with adults, children were more likely to have generalized seizures (p 5 0.007) and move-
ment disorders (p 5 0.01) and less likely to have a tumor (p 5 0.01). The main epitope targets
were in the a1/b3 subunits of the GABAAR.
Conclusions: Anti-GABAAR encephalitis is characterized by frequent seizures and distinctive
multifocal cortical-subcortical MRI abnormalities that provide an important clue to the diagnosis.
The frequency of symptoms and comorbidities differ between children (more viral-related) and
adults (more tumor-related). The disorder is severe but most patients respond to treatment.
Neurology® 2017;88:1012–1020
GLOSSARY
CBA 5 cell-based assay; FLAIR 5 fluid-attenuated inversion recovery; GABAAR 5 GABAA receptor; HHV6 5 human
herpesvirus 6; HSV1 5 herpes simplex 1; PSCT 5 peripheral stem cell transplantation.
The GABAA receptor (GABAAR) is a ligand-gated chloride channel that mediates fast inhibitory
synaptic transmission in the CNS. At the synapse, most GABAARs contain 2 a subunits, 2 b
subunits, and 1 g subunit, arranged as g-b-a-b-a. Pharmacologic or genetic alteration of this
receptor causes seizures,1–7 and we recently reported that human autoantibodies to the a1 and
b3 subunits associate with seizures and status epilepticus in the context of autoimmune enceph-
alitis.8 Since then, the g2 subunit was also found to be a target of autoantibodies in one patient,9
and subsequently confirmed in other cases.10 Recognition of anti-GABAAR encephalitis is
important because the seizures may be refractory to antiepileptic drugs unless the autoimmune
response is treated. It is unclear whether the clinical features associated with antibodies against
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the g2 subunit are different from those asso-
ciated with antibodies against the a1 and b3
subunits. Moreover, since anti-GABAAR
encephalitis was described recently, the spec-
trum of symptoms has not been fully defined.
We describe the clinical, MRI, and immuno-
logic features of 17 newly identified patients
and 9 previously reported but not investigated
for antibodies against the g2 subunit of the
receptor.
METHODS Patients, controls, clinical definitions, and
sample collection. Between April 2013 and January 2016, we
investigated the sera or CSF of 2,914 patients with suspected
autoimmune neurologic disorders. We included in the current
study only those patients who fulfilled the following 3 criteria
(figure e-1 at Neurology.org): (1) syndrome compatible with
possible autoimmune encephalitis,11 (2) serum or CSF
reactivity with neuropil of rat brain suggesting a cell surface or
synaptic target antigen, and (3) reactivity in a specific GABAAR
cell-based assay (CBA) using live HEK cells expressing a1b3 or
a1b3g2 subunits. In addition, we included 9 patients (1–6, 9,
11, and 12 from our original report describing the GABAAR
antibodies) whose serum or CSF fulfilled the above criteria; the
other 9 patients from that study were excluded because the
antibodies did not show brain reactivity.8
Clinical information was obtained from questionnaires com-
pleted by physicians. The severity of symptoms was evaluated by
the modified Rankin Scale.12 The outcome at the last follow-up
was defined as complete recovery (able to return to all previous
activities), partial recovery (objective improvement but unable to
return to all activities), no improvement, or death. Controls (total
461) for tissue immunohistochemistry and CBA antibody studies
included serum or CSF of 169 patients with autoimmune
encephalitis (paraneoplastic or nonparaneoplastic), 114 with
opsoclonus-myoclonus, 117 with stiff-person syndrome, 20 with
neurodegenerative disorders, and 41 healthy blood donors.
Immunohistochemical studies. All samples were screened for
reactivity with rat brain sections using previously reported immu-
nohistochemical methods.8,13 Specific neuronal surface targets
were investigated with CBA that included 13 autoantigens
(NMDAR, AMPAR, GABABR, GABAAR, LGI1, CASPR2,
DPPX, GlyR, GAD65, IgLON5, mGluR5, Dopamine2R,
neurexin-3a), as reported.13–18 The CBA for GABAAR antibodies
is described in the supplemental material.
Standard protocol approvals, registrations, and patient
consents. All patients gave written informed consent for use of
samples and clinical information. This study was approved
by the Institutional Review Board of the Hospital Clinic in
Barcelona, Spain.
Statistical analysis. Comparisons between adults and children,
and between patients with and without tumor, were assessed with
the 2-tailed Fisher exact test and Mann-Whitney U test. Results
,0.05 were regarded as statistically significant.
RESULTS Seventeen newly identified and 9 previ-
ously reported patients fulfilled the indicated criteria
Figure 1 Reactivity of patient’s antibodies with the GABAA receptor (GABAAR)
Rat brain immunostaining with CSF of a patient with antibodies against the a1, b3, and g2 subunits of the GABAAR (A),
compared with that of another CSF sample containing antibodies against a1 and b3 subunits (C). Note the remarkable
similarity of immunostaining of the samples of both patients. (B, D) Reactivity of the same patients’ CSF samples with the
corresponding HEK cells expressing the a1b3g2 subunits (B), and HEK cells expressing the a1b3 subunits (D). For patients
with antibodies against a1b3 subunits, adding the g2 subunit did not increase the intensity of reactivity with a1b3 (data not
shown). The CSF of a patient without these antibodies serves as control (E, F). Scale bar rat brain 5 2 mm, scale bar HEK
cells 5 10 mm.
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for anti-GABAAR encephalitis. These 26 patients, but
none of the 461 controls, had antibodies identified
with rat brain immunostaining and live HEK CBA
expressing a1b3 subunits of the GABAAR (figures 1
and e-2). Among the 16 patients with paired serum
and CSF samples, 14 had antibodies in both and 2
only in serum. The samples of all 26 patients reacted
with live neurons (data not shown) similarly to those
previously reported. Parallel studies in all 461 con-
trols with live HEK cells expressing a1b3g2 subunits
of the GABAAR (expression of individual subunits
confirmed with commercial antibodies) did not reveal
additional patients, indicating the absence of patients
with isolated g2 antibodies in our study. Indeed, all
patients with g2 antibodies (8/26, 31%) also had
antibodies against the a1 or b3 subunits (see supple-
mental material and figure e-3).
Detailed clinical features of the 17 newly identified
patients are described in table 1, and of the 26 pooled
cases in tables 2 and e-1. The median age of all patients
was 40.5 years (interquartile range 48.5 [13.75–62.35]
years), including 15 adults and 11 children; 13 were
(50%) female. The median follow-up was 9 months
(range 2 weeks–7 years), and the median duration of
symptoms by the time of diagnosis was 2 months
(range 1 week–5 years).
Tumor, viral, and other autoimmune associations
occurred in 11 patients (table 1). Seven of these pa-
tients had an underlying tumor: 4 thymoma (1 with
LGI1 antibodies, 1 with myasthenia), 1 small-cell lung
cancer, 1 rectal cancer in association with HIV, and 1
multiple myeloma treated with autologous peripheral
stem cell transplantation (PSCT) and lenalidomide
(the autoimmune encephalitis developed 10 months
after PSCT). Another 2 patients developed the auto-
immune encephalitis a few weeks after viral encepha-
litis, one post herpes simplex 1 (HSV1) encephalitis
and the other post human herpesvirus 6 (HHV6)
encephalitis. By the time of the autoimmune enceph-
alitis, both patients had GABAAR and NMDAR anti-
bodies that were not present during the viral infection.
Another 2 patients had myasthenia without thymoma.
One of the patients with coexisting GABAAR and
NMDAR antibodies is described in the supplemental
material; the patient with thymoma and LGI1 anti-
bodies has been reported previously.19
The most frequent (core) symptoms included seiz-
ures (23/26, 88%), cognitive impairment (n5 16/24,
67%, 2 babies excluded from analysis), altered behav-
ior (12/26, 46%), decreased level of consciousness (11/
26, 42%), and movement disorders (9/26, 35%). Sta-
tus epilepticus occurred in 11 (48%) of the 23 patients
with seizures, and 7 (64%) of them required pharma-
cologic coma. Seizures accompanied by at least another
core symptom occurred in 23/26 (88%) patients and
by at least 2 core symptoms in 14/26 (54%). Nine
(35%) patients developed abnormal movements,
including 7/11 (64%) children who showed orofacial
dyskinesias, dystonic postures, or generalized choreoa-
thetosis, and 2/15 (13%) adults, both showing facial
twitches and cramps. Two of the 11 children devel-
oped the symptoms as part of a postviral encephalitis
(coexisting with NMDAR antibodies) and 1 after vac-
cination for yellow fever (without NMDAR antibod-
ies). The latter was a 10-month-old baby girl (patient
8, video) who developed a clinical picture that initially
suggested anti-NMDAR encephalitis, including dysau-
tonomia and orofacial and limb dyskinesias without
NMDAR antibodies in serum and CSF.
CSF was abnormal in 15 of 26 (58%) patients
including pleocytosis (6–154 leukocytes/mm3),
increased protein concentration (0.52–0.85 g/L), or
oligoclonal bands (table 2). EEG was available for 21
patients: 16 (76%) had epileptiform activity, mostly
unilateral or bilateral periodic epileptiform discharges
involving the temporal lobes (9 associated with focal or
diffuse slow activity) and 5 (24%) had slow activity.
Brain biopsy, performed in patient 15, demonstrated
mild parenchymal and perivascular lymphocytic infil-
trates without vessel wall involvement, and microglial
activation (data not shown).
T2/fluid-attenuated inversion recovery (FLAIR)
brain MRI abnormalities were identified in 23/26
(88%) patients. In 20 (77%), the abnormalities were
multifocal, involving both gray and white matter in 2
or more of the following regions: temporal (95%, 16
bilateral, 3 unilateral), frontal (65%, 10 bilateral, 3
unilateral), parietal (25%, 3 bilateral, 2 unilateral),
occipital (15%, 2 bilateral, 1 unilateral), basal ganglia
(15%), cerebellum (10%), or brainstem (5%). Only 2
patients had isolated unilateral involvement of the
temporal lobe, another patient had isolated unilateral
parietal involvement, and 3 had normal MRI. The
multifocal abnormalities involved cortical and subcor-
tical regions (figure 2), without diffusion restriction
(except for patient 7) and without gadolinium
enhancement (except for patient 14, who had focal
gyriform leptomeningeal enhancement, and 16, who
had mild hippocampal enhancement). The multifocal
T2/FLAIR changes were asynchronous, with some
appearing while others were disappearing during the
course of the disease. In one of the patients (case 17),
the MRI abnormalities persisted during short periods
(4–6 weeks) in which the patient was remarkably free
of seizures or other symptoms.
Treatment information was available for 23 pa-
tients: 13 (56%) received first-line immunotherapy
(corticosteroids, plasma exchange, IV immunoglobu-
lin), 8 (35%) first- and second-line immunotherapy
(rituximab, azathioprine, cyclosporine, or cyclophos-
phamide), and 2 (9%) were only treated with anti-
epileptics. At the last follow-up, 18 of 21 (86%)
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Table 1 Main clinical features and antibody specificity in 17 new patients with anti-GABAA receptor (GABAAR) encephalitis
Patient, sex,
age, y
Prodromal
features
Tumor; other
autoimmune disorders
Main clinical features; mRS at
the peak of disease CSF EEG
MRI (increased T2/FLAIR
signal)
Immunotherapy
and tumor
treatment
Last follow-up, mo;
recovery; mRS
GABAAR subunit;
additional Ab
1, F, 58 Fatigue, fever Thymoma (identified
at diagnosis)
Memory loss; 2 Normal Intermittent slowing Bilateral insula and basal
ganglia
Steroids,
thymectomy
9; partial; mRS 1 S: 1/640; CSF: 1/
20; a1, b3
2, F, 88 None Thymoma (identified
at diagnosis)
dLOC, cognitive decline, L
hemiplegia; 5
Normal NA R temporal, bilateral frontal
lobes
PE, thymectomy 10; partial; mRS 3 S: NA; CSF: 1/20;
a1
3, F, 74 Headache None Personality change, apathy,
anxiety, memory loss, speech
disorder, dLOC, focal seizures,
SE; 5
Normal Bilateral temporal PED L temporal lobe, mild
hippocampal Gd1
Steroids, AZA 2; partial; mRS 2;
died 6 months later
of sepsis
S: NA; CSF: 1/20;
a1, b3
4, M, 60 None None Focal auditory seizures; R facial
twitches, R hemibody
paresthesia, dysarthria and
aphasia; 5
Normal NA L temporal and bilateral
frontal lobes
Steroids 12; partial; mRS 2 S: 1/160; CSF: 1/
40; a1, b3, g2
5, F, 66 Skin rash,
vomiting
Thymoma (preceded
encephalitis)
Right arm paresthesia; 1 Normal NA Bilateral frontal, temporal,
parietal lobes
Steroids,
thymectomy
3; partial; mRS 1 S: 1/40; CSF: 1/20;
a1, g2
6, M, 36 HIV Rectal cancer
(preceded encephalitis)
Seizures, confusion, dLOC; 2
months later hearing difficulty,
slurred speech; 4
Normal Intermittent diffuse
slowing
L operculum and bilateral
temporal lobes
Steroids, cancer
treatment
12; partial; mRS 2 S: 1/160; CSF: 1/
20; b3, g2
7, M, 62 None 10 months
posttransplant for
multiple myeloma
Seizures, cognitive
deterioration, altered mental
status, dLOC, coma; 5
Normal Diffuse slowing Fontal, temporal, and occipital
lobes with diffusion restriction
Steroids, PE 2; complete; mRS 0 S: .1/1280; CSF:
NA; b3
8, F, 10 mo Yellow fever
vaccine
None Focal motor seizures,
involuntary movements, dLOC,
coma, SE, autonomic instability;
5
Normal Diffuse slowing,
epileptiform activity
Normal CT and MRI Steroids, IVIg 8; partial; mRS 4 S: .1/640; CSF: 1/
40; b3
9, M, 15 mo HSV1
encephalitis
None 8 weeks after HSE: irritability,
focal motor refractory seizures,
SE, choreoathetosis, ataxia,
dysphagia; 5
53 WBC, EP
(0.83).
Generalized bilateral
epileptiform activity
New increased T2/FLAIR
signal in bilateral frontal
and temporal lobes
Steroids, PE,
RTX
14; partial; mRS 4 S: 1/80; CSF: 1/20;
a1, b3, g2; NMDAR
10, F, 45 Headache,
flushing
Myasthenia gravis,
metastatic thymoma
Focal motor seizures, mood and
behavioral change, memory loss,
dysautonomia; new pleural
metastasis; 3
EP R temporal PED and L
epileptiform activity
Bilateral temporal lobes Steroids, PE,
surgical removal
of metastasis
3; complete; mRS 0 S: .1/640; CSF: 1/
40; a1, b3; LGI1
11, F, 14 Headache,
malaise
None Seizures, abnormal
movements; NA
51 WBC NA Normal (1 week from disease
onset)
NA NA S: 1/40; CSF: NA;
a1, b3, g2
12, F, 63 None Small cell lung cancer
(identified at diagnosis)
Focal motor seizures, memory
loss, personality change, ataxia,
gait problems; 6 months later:
hallucinations, choreiform
movements; 3
44 WBC, EP
(0.52), OCB
Diffuse slowing, L
hemisphere PED
Bilateral temporal lobes and
basal ganglia
NA NA S: 1/40; CSF:
negative; a1, b3, g2
13, M, 53 Headache,
vomiting
Myasthenia gravis; no
tumor
Focal motor seizures with
secondary generalization,
cognitive decline; 4
52 WBC Diffuse slowing, L PED Bilateral temporal lobes, L
frontal lobe and R occipital lobe
No
immunotherapy
(only AED)
1.5; partial; mRS 1 S: NA; CSF: 1/40;
a1, b3
14, M, 16 Headache,
weight loss,
vomiting
None Seizures, personality change,
memory loss, insomnia, L
dysmetria and weakness,
dysautonomia; 3
10 WBC, OCB Diffuse and focal
slowing, bilateral PED
Bilateral temporal, frontal and
occipital lobes, focal
leptomeningeal Gd1
Steroids, IVIg,
PE, RTX
3; complete; mRS 0 S: 1/320; CSF: 1/
80; b3, g2
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patients treated with immunotherapy (and tumor
removal when appropriate) had partial (n 5 13,
72%) or complete (n 5 5, 28%) recovery, and the
other 3 (14%) patients died of sepsis, which in 2 was
associated with status epilepticus; none of the patients
who died had a tumor. One of the 2 patients who did
not receive immunotherapy showed partial improve-
ment (case 13), and the other was lost to follow-up
(unknown outcome). At the last follow-up, none of
the 26 patients has had a relapse. One patient (case
17) developed anti-GABAAR encephalitis 1 year after
a first episode of seizures successfully treated with
antiepileptic drugs. However, it is unclear whether
the first episode was related to anti-GABAAR enceph-
alitis given that no CSF, MRI, or antibody studies
were obtained.
Compared to adults (table 2), children were more
likely to develop generalized seizures (11/11, 100% vs
7/15, 47%, p 5 0.007), movement disorders (7/11,
64% vs 2/15, 13%, p5 0.01), and CSF abnormalities
(10/11, 91% vs 5/15, 33%, p5 0.005), and less likely
to have a tumor (1/10, 10% vs 9/15, 60%, p5 0.01).
Despite these findings, the outcome was not signifi-
cantly different between the age groups (p 5 0.06).
Compared to patients without tumor (table e-1),
those with tumor were older (median 56.5 vs 16 years
in patients without tumor, p 5 0.006) and less fre-
quently had generalized seizures (4/10, 40% vs 13/15,
87%, p 5 0.02); the outcome, however, was similar
(p 5 0.14).
Detection of antibodies against the g2 subunit,
which in all cases occurred in association with anti-
bodies against the a1 or b3 subunits, did not segre-
gate with symptoms or paraclinical findings different
from those in patients without g2 subunit antibodies
(data not shown).
DISCUSSION We report 17 new patients with anti-
GABAAR encephalitis and review 9 previously
reported cases providing the main clinical and radio-
logic clues that assist in the differential diagnosis of
this disorder in children and adults, tumor and viral
associations, and the main subunit targets of the anti-
bodies, the a1 and b3 subunits of the GABAAR.
Our current findings confirm that seizures are the
most frequent clinical manifestation of this disorder.
Combined with data from our previous study, up to
88% of the patients had seizures, usually at symptom
presentation, and frequently accompanied by status ep-
ilepticus that often required pharmacologically induced
coma. Status epilepticus (along with sepsis) may have
contributed to the death of 2 patients. In all patients,
the seizures were accompanied by at least one of the
following core symptoms: cognitive impairment,
decreased level of consciousness, altered behavior, or
movement disorders. Interestingly, children were more
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likely to have generalized seizures and movement disor-
ders and less likely to have an underlying tumor than
adults. These age-related symptoms may result from
the combination of specific antibody effects on synap-
tic circuits (e.g., antibody-mediated decrease of recep-
tors) and increased vulnerability of some areas of the
developing brain (hippocampus, basal ganglia) to
inflammatory disorders. For example, other
inflammation-related epileptic conditions (e.g., febrile
infection-related epilepsy syndromes20) and movement
disorders (e.g., postinfectious Sydenham chorea21)
occur almost exclusively in children. In addition, in
children, GABAAR antibodies may develop as postviral
encephalitis and coexist with NMDAR antibodies,
in which case the resulting symptoms (seizures,
dyskinesias, choreoathetosis) are likely a manifesta-
tion of the combined presence of NMDAR
antibody–mediated mechanisms.
Considering the clinical similarities among many
forms of autoimmune encephalitis, an important find-
ing of our study is the association of anti-GABAAR
encephalitis with multifocal unilateral or bilateral
cortical-subcortical T2/FLAIR MRI abnormalities.
These T2/FLAIR abnormalities can manifest asyn-
chronously during the course of the disease (some
appear while others disappear), sometimes with lim-
ited correlation with the patient’s symptoms, and
rarely enhance with contrast. These MRI findings
are important not only because they are frequent
(77% of the patients) but also because they rarely
occur in other autoimmune encephalitis, providing
a valuable clue to the clinical recognition of
GABAAR autoimmunity.
The experience gained from this and our previous
study suggests that 40% of patients with anti-GABAAR
encephalitis have tumors, mostly thymomas, and
less commonly, other neoplasms (e.g., Hodgkin
lymphoma, multiple myeloma) that may cause alter-
ations of the immunologic system, perhaps leading to
autoimmunity. Patients with a tumor were older (only
1 of 11 pediatric patients had a tumor; Hodgkin
lymphoma in a 16-year-old patient) and less likely to
have seizures than those without tumor, probably due
to the general predisposition of children with inflam-
matory brain disorders to have seizures. Four adult
patients had thymoma: 1 of them, previously re-
ported,19 had a history of several tumor relapses without
development of encephalitis until the last relapse, which
also associated with LGI1 antibodies. Interestingly, the
thymoma of this patient expressed both LGI1 and GA-
BAAR proteins, and the clinical picture appeared to be
driven by the GABAAR immune response showing
widespread multifocal (not hippocampal limited) T2/
FLAIR abnormalities, which are highly unusual in
anti-LGI1 encephalitis. This clinical case resembled 2
reported patients with anti-GABAAR encephalitis in
association with invasive thymoma, coexisting antibod-
ies (LGI1 or Caspr2), myasthenia gravis (in one), and
multifocal T2/FLAIR MRI abnormalities.9 We did not
find another predominant tumor type among our pa-
tients with malignancies, as reported in previous stud-
ies.9,10 It is unclear whether the history of HIV,
Table 2 Clinical features in children and adults with anti–GABAA receptor
(GABAAR) encephalitis (26 patients)
Total
(26) Children (11) Adults (15)
p
Value
Demographics
Median age (range), y 40.5 13 (2.5 mo–16 y) 59 (28–88)
Female 13/26 6/11 (55%) 7/15 (47%) 1
Clinical association
Tumor 10/25 1/10 9/15 0.01a
Other autoimmune diseases 5/26 0/11 5/15 0.05
Clinical manifestations
Prodrome 9/25 4/10 5/15 1
Generalized seizures 18/26 11/11 7/15 0.007a
Focal seizures 21/26 8/11 13/15 0.61
Status epilepticus/seizures (any
type)
11/23 6/11 5/12 0.68
Decreased level of consciousness 11/26 4/11 7/15 0.7
Behavioral changes 12/26 5/11 7/15 1
Cognitive decline 16/24 6/9 10/15 1
Movement disorders 9/26 7/11 2/15 0.01a
Dysautonomia 4/25 3/10 1/15 0.26
Clinical severity
mRS ‡4 at the peak of disease 15/22 7/10 8/12 0.24
Admission to ICU 12/26 7/11 5/15 0.23
Complementary studies
MRI multifocal abnormalities 20/26 8/11 12/15 1
EEG epileptiform discharges 16/21 8/10 8/11 1
EEG focal/diffuse slowing 12/21 7/10 5/11 0.38
CSF abnormal (cell count, proteins,
or OCB)
15/26 10/11 5/15 0.005a
Additional antineuronal antibodies 7/26 4/11 3/15 0.4
Immunotherapy
First-line alone (steroids, PE, IVIg) 13/23 4/10 9/13
First- and second-line (AZA, CTX,
CyA, RTX)
8/23 5/10 3/13
No immunotherapy 2/23 1/10 1/13
Outcome
Partial recovery 14/22 8/10 6/12 0.06
Complete recovery 5/22 1/10 4/12
Death 3/22 1/10 2/12
Abbreviations: AZA 5 azathioprine; CTX 5 cyclophosphamide; CyA 5 cyclosporine; ICU 5
intensive care unit; IVIg 5 IV immunoglobulins; mRS 5 modified Rankin Scale; OCB 5
oligoclonal bands; PE 5 plasma exchange; RTX 5 rituximab.
a Significant.
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vaccination against yellow fever, or a peripheral stem
cell transplant for multiple myeloma in 3 of our pa-
tients played a role in triggering the GABAAR immune
response. However, it is interesting to note that post-
transplant immunosuppressed patients can develop
autoimmune encephalitis, as has been shown in pa-
tients with anti-NMDAR and anti-LGI1
encephalitis.22,23
The development of anti-GABAAR encephalitis as
postviral encephalitis (HSV1 and HHV6) expands the
number of receptors that can be involved as targets of
postviral brain autoimmunity. This and previous find-
ings24 support the concept of autoimmunity triggered
by extensive antigen release by infected neurons under-
going degeneration. A mechanism of viral mimicry is
less likely because the 2 patients with this complication
developed de novo synthesis of antibodies against 2
different targets (GABAAR and NMDAR) during the
weeks following the viral encephalitis.
All patients’ serum or CSF antibodies recognized
the a1 or b3 subunits of the GABAAR, with 31% of
the cases showing coexisting antibodies against the g2
subunit. None of the patients had isolated antibodies
against the g2 subunit, and the presence of these anti-
bodies along with antibodies to a1 or b3 subunits did
not reveal a specific subphenotype (data not shown),
suggesting that CBA expressing a1b3 or a1b3g2 can
be used for comprehensive antibody testing. In a pre-
vious study in which the clinical and paraclinical infor-
mation (CSF, MRI, or EEG) were limited or not
available for many patients, antibodies directed only
against the g2 subunit were identified in 5 cases.10
Each of these patients had a different syndrome or
suspected etiology (celiac disease, psychological disor-
der, mild cognitive impairment, pathologically con-
firmed Huntington disease, focal epilepsy) and only
1 received immunotherapy, suggesting a low index of
conviction among the treating physicians for an auto-
immune cause. In contrast, our current clinical find-
ings associated with brain tissue reacting antibodies
and a1b3 subunit specificity (irrespective of g2 sub-
unit antibodies) show a more homogeneous clinical
and radiologic syndrome, and 21 of 23 patients
received immunotherapy.
It is premature to indicate whether serum or CSF
should preferentially be tested. We have identified
GABAAR antibodies in serum, but not CSF, of pa-
tients with other disorders such as stiff-person syn-
drome or opsoclonus-myoclonus.8 Interestingly, the
samples of those patients do not react with brain
tissue or cultured neurons, suggesting other epitope
targets of unclear clinical relevance. This finding and
the possible coexistence of CSF or serum antibodies
against other synaptic or cell surface proteins8–10 sug-
gests caution in selecting only serum or CSF for anti-
body testing, and for these reasons we prefer
determining antibodies in both samples. A compre-
hensive approach to antibody testing using CBA with
both serum and CSF or if only serum is available
confirming the results with brain tissue immunohis-
tochemistry has been recommended for most anti-
bodies against cell surface or synaptic proteins.11 In
our experience with this and other autoantibodies, the
parallel demonstration of antibody reactivity using
brain tissue and CBA has more clinical value than
CBA alone (irrespective of the titers of this assay),
as shown here in some cases.
Despite the limitations of being a retrospective
study and that the disease is infrequent, the findings
of this study are important in helping to recognize
this potentially lethal disorder. Current experience
suggests that anti-GABAAR encephalitis should be
suspected in patients with encephalitis predominantly
manifesting with seizures and multifocal cortical-
subcortical T2/FLAIR MRI abnormalities that usu-
ally involve the temporal lobes (95% of cases). The
disorder can affect very young children (the youngest
Figure 2 MRI findings in 2 patients with anti–GABAA receptor (GABAAR)
encephalitis
(A, B) MRI from patient 7, obtained on day 30 after symptom onset, shows extensive, conflu-
ent fluid-attenuated inversion recovery (FLAIR) abnormalities involving the left occipital lobe
and the frontal and temporal regions, bilaterally, with moderate diffusion restriction (not
shown). (C) MRI from patient 14, obtained on day 45 after symptom onset, shows extensive
multiple cortical-subcortical FLAIR abnormalities involving bilateral frontal, temporal, and
parietal-occipital lobes, without diffusion restriction, but mild gyriform leptomeningeal
enhancement in the right temporal pole (not shown). Biopsy was performed in the right fron-
tal region. (D) Follow-up MRI obtained 2.5 months later (4 months after symptom onset)
shows substantial improvement and resolution of most abnormalities.
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in this study was 2.5 months) and adults. In younger
patients, the disorder may be confused with anti-
NMDAR encephalitis due to the common presence
of dyskinesias, although it is important to keep
in mind that both disorders may overlap in the context
of postviral autoimmune encephalitis. Compared
with other autoimmune encephalitis, anti-GABAAR
encephalitis seems to be less responsive to treatment
than NMDAR encephalitis. Although 86% of the pa-
tients showed responses to treatment (first- and second-
line therapies and tumor treatment if needed), only
28% had full recovery (and only one of them was
a child), and the other 14% died, emphasizing the need
for prompt recognition and treatment of the disorder.
Future studies should focus on clarifying the frequency
of GABAAR antibodies in patients with postviral auto-
immune encephalitis, the preferential occurrence of
these antibodies in serum or CSF, and whether prompt
treatment improves the degree of neurologic recovery.
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